Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
Status:
Completed
Trial end date:
2021-05-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find a dose of intravitreal bevacizumab that is lower than
currently used for severe retinopathy of prematurity (ROP), is effective in this study, and
can be tested in future larger studies.
Phase:
Phase 1
Details
Lead Sponsor:
Jaeb Center for Health Research
Collaborators:
National Eye Institute (NEI) Pediatric Eye Disease Investigator Group